替非珠单抗
| 单克隆抗体 | |
|---|---|
| 种类 | 完整抗体 |
| 目標 | 聚集因子A |
| 臨床資料 | |
| 商品名 | Aurexis |
| 其他名稱 | 特非珠单抗、INH-H 2002 |
| ATC碼 |
|
| 识别信息 | |
| CAS号 | 521079-87-8  |
| ChemSpider | |
| UNII | |
| KEGG | |
| 化学信息 | |
| 化学式 | C6548H10122N1730O2034S44 |
| 摩尔质量 | 147,035.72 g·mol−1 |
替非珠单抗（INN：Tefibazumab）是一种人源化单克隆抗体，用于治疗金黄色葡萄球菌的严重感染。可能的适应症包括治疗患有囊性纤维化的2a期患者的金黄色葡萄球菌[1]和耐甲氧西林金黄色葡萄球菌。[2]该药物由Inhibitex开发的。[3]
参见
[编辑]参考资料
[编辑]- ^ Clinical trial number NCT00198289 for "Aurexis in Cystic Fibrosis Subjects Chronically Colonized With Staphylococcus Aureus in Their Lungs" at ClinicalTrials.gov
- ^ Pan A, Lorenzotti S, Zoncada A. Registered and investigational drugs for the treatment of methicillin-resistant Staphylococcus aureus infection. Recent Patents on Anti-Infective Drug Discovery. January 2008, 3 (1): 10–33. PMID 18221183. doi:10.2174/157489108783413173.
- ^ John JF. Drug evaluation: tefibazumab--a monoclonal antibody against staphylococcal infection. Current Opinion in Molecular Therapeutics. October 2006, 8 (5): 455–60. PMID 17078388.